

# TABLE OF CONTENTS

## Book 8

Preface .....	i
Editorial Board .....	ii
Book 8 Panel .....	iii
Disclosure of Potential Conflicts of Interest .....	vii
Continuing Education and Program Evaluation Instructions .....	viii
Roles of ACCP and BPS .....	xi

## Chronic Illnesses I

CHRONIC PAIN MANAGEMENT: A DISEASE-BASED APPROACH	
Learning Objectives .....	1
Introduction .....	1
Pathophysiology of Pain .....	2
Nociceptive Pain .....	2
Transduction .....	2
Transmission .....	3
Perception .....	3
Modulation .....	4
Inflammatory Pain .....	4
Peripheral Sensitization .....	4
Phenotypic Switch .....	4
Central Sensitization .....	4
Neuropathic Pain .....	5
Ectopic Excitability .....	6
Structured Reorganization .....	6
Functional Pain .....	6
Analgesics .....	6
Nonopioid Analgesics .....	6
Acetaminophen .....	6

Nonsteroidal Anti-inflammatory Drugs .....	6
Tramadol .....	7
Opioids .....	7
Adjuvants .....	9
Antiepileptic Drugs .....	11
First-generation AEDs .....	11
Second-generation AEDs .....	11
Gabapentin .....	12
Other Second-generation AEDs .....	12
Antidepressant Drugs .....	12
Tricyclic Antidepressant .....	12
Selective Serotonin Reuptake Inhibitors .....	13
Serotonin-norepinephrine Reuptake Inhibitors and Other Antidepressant Drugs .....	13
Antiarrhythmic Drugs and Local Anesthetics .....	13
Topical and Other Adjuvant Analgesics .....	14
Capsaicin .....	14
Other Adjunctive Analgesics .....	14
Assessment of Pain .....	14
Pain Screening and Assessment .....	14
Knee Pain .....	15
Foot Pain .....	15
Pathogenesis of V.H.'s Pain .....	17
Treatment Plan for V.H. ....	17
Painful Diabetic Neuropathy .....	18
Pathophysiology .....	18
Assessment .....	18
Management .....	19
Post-herpetic Neuralgia .....	21
Pathophysiology .....	21
Assessment .....	21
Management .....	22
Low Back Pain .....	23
Pathophysiology .....	23
Assessment .....	24
Management .....	28
Acute LBP .....	28
Chronic LBP Management .....	29
Chronic Spinal Cord Injury Pain .....	31

Pathophysiology	31
Assessment	31
Management	33
The Role of the Pharmacist in Chronic Pain Management	35
Annotated Bibliography	35
<b>Self-Assessment Questions</b>	37

**RHEUMATOLOGY: OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS**

Learning Objectives	41
Introduction	41
Pathophysiology of Osteoarthritis	42
Definition and Epidemiology	42
Etiology and Pathophysiologic Findings	42
Classification and Risk Factors	43
Clinical Features	44
Diagnosis	44
Prognosis	44
Pathophysiology of Rheumatoid Arthritis	44
Definition and Epidemiology	44
Etiology and Pathophysiologic Findings	46
Clinical Features	47
Joint Involvement	47
Extra-articular Involvement	48
Diagnosis	48
Prognosis	48
Quality Patient Care	49
General Therapeutic Goals and Outcomes for Arthritis	49
Pharmacotherapy	49
Symptomatic Therapies for Osteoarthritis and Rheumatoid Arthritis: Topical Agents	49
Capsaicin	49
Other Topical Agents	50
Symptomatic Therapies for OA and RA: Systemic Analgesics/Anti-inflammatory Drugs	50
Acetaminophen	50
Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitors	51
Efficacy of NSAIDs and COX-2 Inhibitors	52
Adverse Effects of NSAIDs and COX-2 Inhibitors	52
Gastrointestinal Complications	52
Therapeutic Strategies to Reduce the Risk of NSAID-Associated Complications	52
Cardiovascular Complications Associated with COX-2 inhibitors and NSAIDs	55
Other Adverse Effects of NSAIDs and COX-2 Inhibitors	57
Considerations for Using NSAIDs and COX-2 Inhibitors	58
Indication of Therapy	58
Selection of Drugs	58
Pharmacoeconomic Factors	59
Applying Clinical Judgment	59

Corticosteroids	59
Intra-articular Injections	59
Systemic Administration of Corticosteroids	61
Viscosupplementation	61
Dietary Supplements	62
Glucosamine and Chondroitin	62
Other Dietary Supplement Products	64
Opioids and Tramadol	64
Disease-modifying Drugs	64
Disease-modifying Osteoarthritic Drugs	65
Disease-modifying Antirheumatic Drugs	65
First-tier DMARDs	65
Hydroxychloroquine	65
Sulfasalazine	66
Methotrexate	66
Leflunomide	67
Tumor Necrosis Factor Antagonists	68
Interleukin-1 Receptor Antagonists	68
DMARDs for Special Situations	69
Tetracyclines	69
Combination DMARD therapy	69
Investigational Drugs for OA and RA	69
Nonpharmacological Therapy	70
Rest and Exercise	70
Nutrition, Weight Loss, and Dietary Therapy	70
Other Measures to Decrease Pain and/or Enhance Functional Ability	70
Treatment Plan	71
Algorithms and Guidelines	71
Osteoarthritis	71
Rheumatoid Arthritis	71
Treatments in Special Populations	71
Geriatric Patients	71
Women of Childbearing Age	72
Patients Taking DMARDs and Implications for Vaccinations	74
Treatment Outcomes and Monitoring	74
Monitoring Outcomes in OA	74
Monitoring Outcomes in RA	75
Monitoring of Drug Therapy in Arthritis	75
NSAIDs	75
DMARDs	75
Corticosteroids	76
Patient Education	76
Arthritis Self-management	76
Drug Therapy	76
Quality Improvement: The Pharmacist's Role	76
Efficiency	76
Efficacy and Effectiveness	76
Conclusion	79
Annotated Bibliography	79
<b>Self-Assessment Questions</b>	83

## Chronic Illnesses II

### SEIZURE DISORDERS IN ADULTS

Learning Objectives	91
Introduction	91
Pathophysiology	91
Definitions	91
Etiology	92
Clinical Characteristics	93
Diagnosis	93
History/Examination	93
Radiological Evaluation	93
Laboratory Evaluation	93
Electroencephalography	94
Epidemiology	94
Prognosis	94
Therapeutic Goals/Outcomes	95
Quality Patient Care	95
Pharmacotherapy	95
Therapy Initiation	95
Pharmacotherapy Refinements	96
Common Severe Adverse Effects/Interactions/ Therapeutic Contraindications	98
Nonpharmacological Therapy	98
Resection	98
Vagus Nerve Stimulation	100
Treatment Plan	100
Therapeutic End Points	100
Guidelines and Algorithm	101
Scottish Intercollegiate Guidelines Network	101
National Institute for Clinical Excellence	101
Prescribing RatiOnally using Decision support In General practice studY	102
Agency for Healthcare Research and Quality Evidence Report	102
American Academy of Neurology Practice Parameters	103
Effectiveness	103
Treatments of Choice in Special Populations	103
Women with Epilepsy	103
Decreased Fertility	103
Risk of Congenital Anomalies and Malformations	103
Management During Pregnancy	104
Postpartum Management	104
Contraception	104
Catamenial Epilepsy	104
Elderly	105
Physiological Changes	105
Comorbid Conditions	105
Adverse Effects	105
Discontinuation of an AED in Seizure-free Patients	105
Monitoring	106
Therapeutic Drug Monitoring	106
Bone Effects	106

Hypersensitivity	106
Adherence	107
System Support for Medication Use Process	107
Documentation That the Pharmacist Should Perform	107
Patient Education	107
Reducing the Patient's Perceived Burden of Illness	108
Assuring That the Patient's Goals of Therapy are Met	108
Special Directions and Precautions for Drug Preparation, Administration, and Use by the Patient	109
Drug Costs	109
Specific Issues Related to Drug or Disease-state Counseling in Different Patient Populations	109
Quality Improvement	110
Conclusion	110
Annotated Bibliography	110
<b>Self-Assessment Questions</b>	113

### HEADACHE

Learning Objectives	117
Introduction	117
Tension-type Headache	118
Pathophysiology	118
Clinical Presentation	118
Diagnosis	118
Treatment Goals	118
Nonpharmacological Therapy	119
Pharmacological Therapy	119
Patient Education	119
Migraine Headache	119
Pathophysiology	119
Clinical Presentation	120
Migraine with Aura	120
Migraine Without Aura	121
Probable Migraine	121
Status Migrainosus	121
Diagnosis	121
Treatment Goals	121
Nonpharmacological Therapy	122
Pharmacological Therapy	122
Drug Management of the Acute Attack	122
Nonspecific Treatment	122
Specific Treatment	123
Ergotamines and Dihydroergotamines	123
Triptans	124
Selection of a Triptan	124
Dosing of the Triptans	125
Prevention	125
General Considerations when Starting a Preventive Drug	125
Antiepileptic Drugs	126
$\beta$ -Blockers	126
Antidepressant Drugs	126

Calcium Channel Blockers	127	Acute Therapy	135
Other Drugs	127	Preventive Therapy	135
Patient-specific Treatment for Migraine	127	Other Therapy	135
Treatments Based on Clinical Situation	127	Patient Education	135
Patient Education	127	Medication Overuse Headache	135
Acute and Preventive Administration,		Conclusion	135
Precautions	127	Annotated Bibliography	135
Drug-drug Interactions	128	<b>Self-Assessment Questions</b>	137
Monitoring	128		
Cluster Headache	128		
Pathophysiology	128	<b>SLEEP DISORDERS</b>	
Clinical Presentation	129	Learning Objectives	141
Diagnosis	129	Introduction	141
Treatment Goals	129	Definition	141
Nonpharmacological Therapy	129	Sleep Stages and Sleep Architecture	141
Pharmacological Therapy	129	Function of Normal Sleep and Consequences of	
Acute	129	Abnormal Sleep	142
Preventive	130	Neurochemistry of Sleep	142
Short-term Preventives	130	Acetylcholine	143
Corticosteroids	130	Norepinephrine	143
Methysergide	130	Histamine	143
Ergotamine	130	Serotonin	143
Long-term Preventives	130	Dopamine	143
Verapamil	130	Orexin	143
Lithium Carbonate	130	Adenosine	143
Antiepileptic Drugs	130	Gamma-aminobutyric Acid	144
Melatonin	130	Classification of Sleep Disorders	144
Patient-specific Treatment	130	Diagnosing, Assessing, and Monitoring of Sleep	
Patient Education	131	Disorders	145
Other Trigeminal Autonomic Cephalgias	131	Subjective Tests	145
Pathophysiology	131	Objective Tests	146
Paroxysmal Hemicrania	131	Therapeutic Goals and End Points	147
Short-lasting Unilateral Neuralgiform Headache		Insomnia	147
Attacks with Conjunctival Injection and Tearing	131	Definition and Consequences of Poor Sleep	147
Cervicogenic Headache	131	Economic Impact	147
Temporomandibular Joint Dysfunction	131	Epidemiology	147
Clinical Presentation	131	Classification and Assessment of Insomnia	147
Diagnosis	131	Treatment	148
Treatment Goals	132	Nonpharmacological Treatment	148
Pharmacological Therapy	132	Sleep Hygiene Education	148
Patient Education	132	Relaxation Therapy	148
Other Primary Headaches	132	Stimulus Control	148
Pathophysiology	132	Sleep Restriction	148
Clinical Presentation	132	Cognitive Restructuring	149
Diagnosis	132	Bright Light Therapy	149
Chronic Transformed Migraine	132	Pharmacological Treatment	149
Chronic-tension Type Headache	132	Benzodiazepine Receptor Agonists	149
New Daily Persistent Headache	132	Memory Impairment and Anterograde	
Treatment Goals	133	Amnesia	150
Pharmacological and Nonpharmacological		Tolerance	151
Therapy	133	Withdrawal and Rebound	151
Chronic Daily Headache with Drug Overuse		Physiological Dependence	151
in the Outpatient Setting	133	Respiratory Depression	152
Chronic Daily Headache with Drug Overuse		Cautions	152
and Admitted for Inpatient Detoxification	133	Drug Interactions	152
Behavior Treatment	135		

Taper Plan	152
Drugs Recently Approved, Awaiting Approval, or Under Investigation	153
Eszopiclone	153
Ramelteon	153
Other	153
Antidepressant Drugs	153
Antihistamine Drugs	154
Antipsychotic Drugs	154
Herbal and Supplement Therapies	155
Melatonin	155
Valerian	156
Treatment Guidelines	156
Patient Education	157
Quality Improvement	157
Hypersomnolent Sleep Disorders	158
Sleep Apnea	158
Obstructive Sleep Apnea	158
Central Sleep Apnea	159
Narcolepsy	159
Description	159
Treatment	159
Sleep-related Movement Disorders	160
Restless Legs Syndrome	160
Description and Epidemiology	160
Treatment	160
Periodic Limb Movements of Sleep	161
Conclusion	161
Annotated Bibliography	161
<b>Self-Assessment Questions</b>	163

### **Chronic Illnesses III**

<b>THROMBOSIS: TREATMENT AND PREVENTION IN PATIENTS WITH CHRONIC ILLNESSES</b>	
Learning Objectives	169
Introduction	169
Preventing Venous Thromboembolism in Hospitalized Medically Ill Patients	169
Preventing VTE in Orthopedic Surgery	171
Pharmacological Options and Comparative Outcomes	172
Total Hip Replacement Surgery	172
Total Knee Replacement Surgery	173
Hip Fracture Surgery	174
Timing of Prophylaxis Initiation	174
Prophylactic Therapy Duration	175
Preventing and Treating VTE in Patients with Hypercoagulable Conditions	175
Therapy Duration in Patients with Hypercoagulable Conditions	176
Primary Prophylaxis in Asymptomatic Carriers	176
Oral Contraceptive Use in Patients with Thrombophilia	177
Preventing and Treating VTE in Patients with a Malignancy	177

VTE Prevention in Malignancy	177
VTE Treatment in Malignancy	178
Anticoagulant Use in Special Populations	179
Monitoring Considerations	180
Obesity	180
Renal Impairment	181
Managing Anticoagulation in Patients Undergoing Invasive Procedures	182
Evaluating Thrombosis Risk	182
Evaluating Bleeding Risk	183
Clinical and Practical Considerations in Designing a Bridge Therapy Plan	184
Conclusion	185
Annotated Bibliography	185
<b>Self-Assessment Questions</b>	187

### **DIABETES: GLYCEMIC CONTROL**

Learning Objectives	193
Introduction	193
Epidemiology	193
Nomenclature	194
Pathophysiology	194
Type 2 Diabetes Mellitus	194
Type 1 Diabetes Mellitus	195
Gestational Diabetes Mellitus and Other Forms	195
Screening	195
Prevention of Diabetes Mellitus	196
Diagnosis	197
Treatment Goals	198
Quality Patient Care	198
Lifestyle Management	198
Diet Management: An Evidence-based Approach	198
Exercise and Activity	198
Stress and Depression Management	199
Pharmacotherapy	199
Nonsulfonylurea Secretagogues	199
Thiazolidinediones	200
Mechanism of Action	200
Clinical Application	200
Adverse Events and Other Clinical Effects	201
New Rapid-acting Insulins	201
Clinical Application	202
New Long-acting Insulins	202
Clinical Application	202
Emerging Therapies	203
Inhaled Insulin	203
Glucagon-like Peptide-1 Agonists	204
DPP-IV Inhibitors	204
Pramlintide	204
Dual PPAR Agonists	204
Treatment Plan	205
Monitoring	206
Traditional Blood Glucose Monitors	206
Nontraditional Monitors	206
Patient Education	207
Low Literacy Issues	207

Self-management Education	207
Quality Improvement	208
The Healthy People 2010 Report on Diabetes	208
Research End Points and Quality of Life Indicators	208
Summary	209
Annotated Bibliography	210
<b>Self-Assessment Questions</b>	213

**MANAGEMENT OF THE COMPLICATIONS  
ASSOCIATED WITH DIABETES**

Learning Objectives	219
Introduction	219
Pathophysiology of Chronic Complications	219
Microvascular Complications	220
Oxidative Stress	220
Advanced Glycation End Products	220
Aldose Reductase (Polyol) Pathway	220
Hexosamine Pathway	221
Protein Kinase C	221
Hormones, Cytokines, Growth Factors, and Vasomotor Mediators	221
Inflammation	221
Macrovascular Complications	221
Abnormal Lipoproteins	222
Prothrombosis	222
Overall Risk of Developing Chronic Complications	222
Microvascular Complications	223
Macrovascular Complications	223
General Management for the Prevention of Complications	223
Glycemic Control	223
Postprandial Hyperglycemia	225
Blood Pressure Control	225
Lipid Control	226
Multifactorial Approach	226
Patient Education	227
Chronic Complications	227
Microvascular	227
Retinopathy	227
Stages of Retinopathy	227
Assessment	228
Management	228
Glycemic Control	228
Blood Pressure Control	228
Other Interventions	229
Surgery	229
Nephropathy	229
Assessment	230
Microalbuminuria	230
Macroalbuminuria	230
Chronic Kidney Failure	230
Management	230
Blood Pressure Control	230
ACE Inhibitors Versus ARBs	231
Protein Restriction	231
Neuropathy	232

Autonomic	232
Cardiovascular	233
Gastrointestinal	233
Genitourinary	233
Other	234
Sensorimotor (Peripheral)	234
Assessment	234
Management of Painful Neuropathy	236
Foot Ulcers	236
Prevention and Management	236
Macrovascular Complications	237
Management	238
Dyslipidemia	238
Hypertension	239
Aspirin	240
Other Preventive Modalities	240
Special Populations	240
Latent Autoimmune Diabetes in Adults	240
Pregnancy	240
Elderly	241
Children	241
Patient Quality Improvement	241
Conclusion	242
Annotated Bibliography	242
<b>Self-Assessment Questions</b>	245

**DERMATOLOGY**

Learning Objectives	251
Introduction	251
Acne Vulgaris	251
Pathophysiology	251
Classification	252
Topical Acne Therapy	252
Benzoyl Peroxide	252
Azelaic Acid	252
Salicylic Acid and Sulfur	253
Retinoids	253
Antibacterial Agents	253
Systemic Acne Therapy	253
Oral Antibiotic Drugs	254
Oral Isotretinoin	254
Systemic Hormonal Therapy	255
Patient Education/Counseling	255
Psoriasis	256
Pathophysiology	256
Topical Therapy	256
Emollients and Keratolytics	256
Anthralin	256
Coal Tar	257
Corticosteroids	257
Calcipotriene	257
Tazarotene	257
Systemic Therapy	258
Methotrexate	258
Cyclosporine	258
Acitretin	259

Phototherapy	259
Biologic Therapy	259
Etanercept	259
Infliximab	260
Efalizumab	260
Alefcept	260
Combination Strategies	260
Atopic Dermatitis	260
Topical Therapy	261
Corticosteroids	261
Tar Preparations	262
Immunomodulators	262
Ultraviolet Light	262
Systemic Therapy	262
Immunosuppressants	262
Corticosteroids	262
Cyclosporine	263
Azathioprine	263
Antimetabolites	263
Other Therapies	263
Antihistamines	263
Wet Dressings/Occlusion	263
Treatment	263
Conclusion	264
Annotated Bibliography	264
<b>Self-Assessment Questions</b>	<b>267</b>